July 24 (SeeNews) - Croatian drug maker Jadran Galenski Laboratorij (JGL) said it closed the first half of 2026 with a consolidated profit before tax of 34.8 million euro ($30 million), up 15.8% year-on-year, as it is entering the largest investment cycle in its history.